Clinical trials: Semaglutide
Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
This study will look at the effects of CagriSema in people with both type 2 diabetes and painful diabetic peripheral neuropathy, compared to placebo.
- Trial name
- NCT06797869
- Testing
- CagriSema (Cagrilintide B and Semaglutide I)
- Where
- 55 sites in United States, Canada and 5 more
- Volunteers
- 142 people
- Sponsor
- Novo Nordisk A/S
Obesity
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism
In this study we will investigate how the medicine cagrilintide affects bone health in women after menopause with obesity during weight loss, compared to treatment with placebo (the dummy medicine with no active substances) and…
- Trial name
- RAMBO (NCT07010432)
- Testing
- Cagrilintide, Semaglutide
- Where
- Denmark
- Volunteers
- 144 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet
In this study we will be looking into how CagriSema influences metabolism (the process by which food is used to supply energy for the body) compared to a diet. CagriSema is a new investigational medicine.
- Trial name
- NCT07184086
- Testing
- CagriSema (Cagrilintide B + semaglutide I), Low Energy Diet
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ)
The main purpose of this study is to evaluate the safety and tolerability of continuing treatment with zovaglutide injection following titration to 2.4 mg semaglutide injection in adult participants with obesity.
- Trial name
- NCT07812597
- Testing
- zovaglutide Arm 1, zovaglutide Arm 2, semaglutide
- Where
- 16 sites in China
- Volunteers
- 210 people
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd
Obesity
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver
This study is open to adults with obesity. People with a body mass index (BMI) in the range from 30 to 40 kg/m2 and a body weight of 70 to 150 kg can participate in the study.
- Trial name
- NCT05202353
- Testing
- BI 456906, Semaglutide
- Where
- Netherlands
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin
This study will look at how much CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema.
- Trial name
- REIMAGINE 3 (NCT06323161)
- Testing
- Cagrilintide, Semaglutide
- Where
- 61 sites in United States, China and 4 more
- Volunteers
- 274 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo).
- Trial name
- OASIS 5 (NCT07770841)
- Testing
- Semaglutide
- Where
- 62 sites in United States, Belgium and 8 more
- Volunteers
- 450 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus (T2DM)
Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus
This is a randomized, double-blind, placebo- and active-controlled, multicenter Phase II clinical trial designed to evaluate the efficacy, safety, and pharmacokinetic characteristics of MWN109 tablets in participants with type 2…
- Trial name
- NCT07801820
- Testing
- MWN109 1, MWN109 2, MWN109 3
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Obesity & Overweight, Mobility Disability
Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
The primary objective of this study is to assess the effect of enobosarm on total body weight
- Conditions
- Obesity & Overweight, Mobility Disability, HOMA-IR
- Trial name
- PLATEAU (NCT07446998)
- Testing
- Enobosarm, Semaglutide (Wegovy) weekly injection
- Where
- 13 sites in United States
- Volunteers
- 239 people
- Sponsor
- Veru Inc.
Overweight, Obesity
Weight Loss in Adults Using Semaglutide (Real-world Study)
The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.
- Trial name
- NCT07627074
- Testing
- Semaglutide
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 237,211 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
The purpose of this clinical study is to look at how well a study medicine called cagrilintide helps people living with excess body weight to lose weight.
- Trial name
- RENEW 4 (NCT07745504)
- Testing
- Cagrilintide
- Where
- 36 sites in United States, Greece and 4 more
- Volunteers
- 285 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity
The purpose of the study is to find out if NNC0721-8060 is safe and how it works in people living with overweight or obesity.
- Trial name
- NCT07767175
- Testing
- NNC0721-8060, Semaglutide
- Where
- 2 sites in United States
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (Wegovy®).
- Trial name
- COURAGE (NCT06299098)
- Testing
- Trevogrumab-Part A, Trevogrumab-Part B and Part C, Garetosmab
- Where
- 60 sites in United States, Puerto Rico
- Volunteers
- 1,005 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Cardiovascular Disease
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular disease.
- Trial name
- REDEFINE 3 (NCT05669755)
- Testing
- Cagrilintide, Semaglutide
- Where
- 633 sites in United States, Argentina and 23 more
- Volunteers
- 7,101 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity
This study will compare the blood levels of cagrilintide and semaglutide when the same dose is given in two different versions of CagriSema. CagriSema is a medicine that combines two medicines called cagrilintide and semaglutide.
- Trial name
- NCT06716307
- Testing
- CagriSema (cagrilintide B and semaglutide I), CagriSema A
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes
This study compares 2 medicines for type 2 diabetes: semaglutide (new medicine) and a dummy medicine (placebo). Semaglutide will be tested to see how well it works compared to the dummy medicine.
- Trial name
- PIONEER TEENS (NCT04596631)
- Testing
- Oral semaglutide
- Where
- 97 sites in United States, Australia and 20 more
- Volunteers
- 132 people
- Sponsor
- Novo Nordisk A/S
Alzheimers Disease
A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease
The study is being conducted to understand how the medicine, semaglutide, affects the immune system and other biological processes in people with Alzheimer's disease.
- Trial name
- NCT05891496
- Testing
- Semaglutide
- Where
- 12 sites in United States, Canada and 4 more
- Volunteers
- 23 people
- Sponsor
- Novo Nordisk A/S
Overweight and Obesity
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity
Novo Nordisk are doing this study to see if semaglutide tablets can be used as a treatment to help people living with overweight or obesity lose weight. This study will look at the change in participants' body weight.
- Trial name
- OASIS 2 (NCT05132088)
- Testing
- semaglutide 50 mg
- Where
- 15 sites in Japan, South Korea
- Volunteers
- 201 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary
Participant will get oral semaglutde as prescribed by the study doctor. The study will last for about 26 ± 4 weeks (5 to 7 months).
- Trial name
- NCT06269120
- Testing
- Oral Semaglutide
- Where
- 19 sites in Hungary
- Volunteers
- 243 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes
This study is testing the effect of a new study medicine NNC0194-0499 in type 1 diabetes. The purpose of the study is to compare the effect of NNC0194-0499 on the blood sugar levels of participants with type 1 diabetes when taken…
- Trial name
- NCT07087795
- Testing
- NNC0194-0499, Semaglutide
- Where
- Germany
- Volunteers
- 96 people
- Sponsor
- Novo Nordisk A/S